Julia Skoraczynski joined the Atherothrombosis and Vascular Biology laboratory as a Master’s student, to pursue her passion of understanding how diseases occur and developing new therapeutics to address unmet clinical needs. Her project focuses on a novel technology for the targeted break down of blood clots that cause strokes and heart attacks, with the aim of improving the efficacy and safety of clot-busting drugs. This technology could reduce the need for interventional techniques that are mostly inaccessible for those outside big-city hospitals. She previously completed her Honours year in the Monash Venom Group, investigating muscle necrosis post snake envenoming.